Biontech provides update on vaccine production status at marburg manufacturing site

Mainz, germany, march 26, 2021 (globe newswire) — biontech se today announced that the european medicines agency (ema) approved the manufacturing of the covid-19 vaccine drug product at the facility in marburg. as part of the process, ema has approved the production of the drug substance, the mrna, at the marburg site over the course of this week. the approvals make biontech's marburg manufacturing site one of the largest mrna vaccine manufacturing sites in europe as well as worldwide with an annual production capacity of up to one billion doses of our covid-19 vaccine, once fully operational. due to optimized operational efficiencies which were initiated last year, biontech has been able to increase the expected annual manufacturing capacity by 250 million doses.
BNTX Ratings Summary
BNTX Quant Ranking